Zanamivir: A review of its use in influenza

Drugs

Volumn 58, Issue 4, 1999, Pages 761-784

  Dunn, Christopher J ^a   Gon, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BUFURALOL; CHLORZOXAZONE; CLAVULANIC ACID; COUMARIN; ETHOXYRESORUFIN; HEMAGGLUTINATION INHIBITING ANTIBODY; IBUPROFEN; INFLUENZA VACCINE; MEPHENYTOIN; MIDAZOLAM; OXYMETAZOLINE; PARACETAMOL; PHENACETIN; PHENYLEPHRINE; PROMETHAZINE; RIMANTADINE; SIALIDASE INHIBITOR; TOLBUTAMIDE; ZANAMIVIR;

BRONCHITIS; CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE DURATION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; KIDNEY FAILURE; LEISURE; MALAISE; NAUSEA; NONHUMAN; NOSE DISEASE; REVIEW; SLEEP; THROAT DISEASE; TONSIL DISEASE; VERTIGO; VIRUS INHIBITION; VIRUS RESISTANCE; VIRUS SHEDDING; WORK;

ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, MICROBIAL; GUANIDINES; HUMANS; INFLUENZA, HUMAN; PYRANS; SIALIC ACIDS; ZANAMIVIR;

INFLUENZA VIRUS; INFLUENZAVIRUS B;

EID: 0032710055     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958040-00016     Document Type: Review

References (68)

1. 1. Lamb RA, Choppin PW. The gene structure and replication of influenza virus. Annu Rev Biochem 1983; 52: 467-506
2. 2. Whittington A, Bethell R. Recent developments in the antiviral therapy of influenza. Expert Opin Ther Pat 1995 Aug; 5: 793-803
3. 3. White JM. Membrane fusion. Science 1992; 258: 917-24
4. 4. Steinhauer DA, Sauter NK, Skehel JJ, et al. Receptor binding and cell entry by influenza viruses. Semin Virol 1992; 3: 91-100
5. 5. Lanzrein M, Schegel A, Kempf C. Entry and uncoating of enveloped viruses. Biochem J 1994; 302: 313-20
6. 2 ion channel protein: a structure-function analysis. J Virol 1994; 68: 1551-63
7. 2 protein has ion channel activity. Cell 1942; 69: 517-28
8. 8. Zhirnov OP. Isolation of matrix protein MI from influenza viruses by acid-dependent extraction with nonionic detergent. Virology 1992; 186: 324-30
9. 9. Zvonarjev AY, Ghendon Z. Influence of membrane (M) protein on influenza A virus virion transcriptase activity in vitro and its susceptibility to rimantadine. J Virol 1980; 33: 583-6
10. 10. Ye ZP, Baylor NW, Wagner RR. Transcription-inhibition and RNA-binding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides. J Virol 1989; 63; 3586-94
11. 11. Wakefield L, Brownlee GG. RNA-binding properties of influenza A virus matrix protein MI. Nucleic Acids Res 1989; 17: 8569-80
12. 12. Martin K, Helenius A. Nuelear transport of influenza ribonucleoproteins: the viral matrix protein (MI) promotes export and inhibits import. Cell 1991; 67: 117-30
13. 13. Jin H, Leser GP, Zhang J, et al. Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J 1997; 16; 1236-47
14. 14. Sha B, Luo M. Structure of a bifunctional membrane-RNA binding protein, influenza virus matrix protein MI. Nature Struct Biol 1997; 4: 239-44
15. 15. Calfee DP, Hayden FG. New approaches to influenza chemotherapy: neuraminidase inhibitors. Drugs 1998 Oct; 56: 537-53
16. 16. Varghese JN, Epa VC, Colman PM. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci 1995 Jun; 4: 1081-7
17. 17. Palese P, Schulman JL. Inhibitors of viral neuraminidase as potential antiviral drugs. In: Oxford JS, editor, Chemoprophylaxis and virus infections of the respiratory tract. v. I. Cleveland: CRC Press Inc., 1977: 189-205
18. 18. Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 1994; 3 (10); 1687-96
19. 19. Schultz-Cherry S, Hinshaw VS. Influenza virus neuruminidase activates latent transforming growth factor ß. J Virol 1996; 70 (12): 8624-9
20. 20. Houde M, Arora DJ. Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase. Cell Immunol 1990; 129 (1): 104-11
21. 21. von Itzstein M, Dyason JC, Oliver SW, et al. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. J Med Chem 1996 Jan; 39 (2): 388-91
22. 22. Snell NJC. New developments in the treatment of viral respiratory tract infections. Expert Opin Invest Drug 1997; 6 (8): 1001-8
23. 23. von Itzstein M, Wu WY, Jin B. The synthesis of 2,3-didehydro2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor Carbohydr Res 1994 Jun 17; 259: 301-5
24. 24. Woods JM, Bethell RC, Coates JA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993 Jul; 37: 1473-9
25. 25. von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993 Jun 3; 363: 418-23
26. 26. Colman PM. A novel approach to anti-viral therapy for influenza. J Antimicrob Chemother. In press
27. 27. Hayden FG, Rollins BS, Madren LK, Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5 Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 1994 Oct; 25: 123-31
28. 28. Thomas GP, Forsyth M, Penn CR, et al. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Res 1994 Aug; 24; 351-6
29. 29. Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996 Jan 24-31; 275: 295-9
30. 30. Hayden FG, Lobo M, Hussey EK, et al. Efficacy of intranasal GGI67 in experimental human influenza A and B virus infection. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Amsterdam: Elsevier Science, 1996: 718-25
31. 31. Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996 Mar; 70: 1818-27
32. 32. Goto H, Bethell RC, Kawaoka Y. Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1997 Nov 24; 238: 265-72
33. 33. Colacino JM, Chirgadze NY, Garman E, et al. A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology 1997 Sep 15; 236; 66-75
34. 34. Barnett J, Dempsey M, Tisdale M, et al. Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor zanamivir (GGI67) during phase II clinical efficacy trials [abstract], 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1: Toronto, 230
35. 35. Gubareva LV, Matrosovich MN, Brenner MK, et al, Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus, J Infect Dis 1998 Nov; 178: 1257-62
36. 36. Cass LMR, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 1-11
37. 37. Cass LMR, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 21-31
38. 38. Peng AW, Stein DS, Grosse C, et al. Sustained concentration in respiratory tract after 10mg zanamivir (ZMV) inhalation [abstract]. Accepted for the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29: San Francisco
39. 39. Cass LMR, Efthymiopoulos C, Marsh J, et al. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Clin Pharmacokinet 1999; 36 Suppl. 1: 13-9
40. 40. Daniel MJ, Barnett JM, Pearson BA. The low potential for drug interactions with zanamivir. Clin Pharmacokinet 1999; 36 Suppl. 1: 41-50
41. 41. Webster A, Boyce M, Edmundson S, et al. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 51-8
42. 42. Dines GD, Bethell R, Daniel M. Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug. Drug Saf 1998 Sep; 19: 233-41
43. 43. Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998 May 10; 47 Suppl. RR-6; 1-26
44. 44. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61
45. 45. MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998 Dec 12; 352: 1877-81
46. 46. Fleming D, Mäkelä M, Pauksens K, et al. 'High risk' and otherwise healthy patients demonstrate alleviation of influenza symptoms 2.5 days earlier following inhaled zanamivir treatment: European study, winter 1997/8 [abstract no. 789]. Proceedings of the Annual Meeting of the Infectious Disease Society of America; 1998 Nov 12-15; Denver
47. 47. Lalezari J, Klein T, Stapleton J, et al. The efficacy and safety of inhaled zanamivir in the treatment of influenza in otherwise healthy and 'high risk' individuals in North America [abstract]. J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 42
48. 48. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997 Sep 25; 337: 874-80
49. 49: Matsumoto K, Ogawa N, Nerome K, et al. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. Antiviral Ther 1999; 4: 61-8
50. 50. Silagy CA, Griffin AD, Lacey LA, et al. Impact of zanamivir on health status, productivity and health care resource use in patients with influenza [abstract]. Clin Infect Dis 1998 Oct; 27: 926
51. 51. Monto AS, Webster A, Keene O, Randomised, placebo controlled studies of inhaled zanamivir in the treatment of influenza A and B - pooled efficacy analysis. J Antimicrob Chemother; Suppl. In press
52. 52. Osterhaus E, Makela MJ, Webster A, et al. The efficacy of inhaled zanamivir in the treatment of influenza B [abstract]. Accepted for the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29: San Francisco
53. 53. Lalezari J, Elliolt M, Keene O. The efficacy and safety of inhaled zanamivir in the treatment of influenza A and B in 'high-risk' individuals - results of phase II and III clinical studies [abstract]. Accepted for the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29: San Francisco
54. 54. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999 Jul 7; 282 (1): 31-5
55. 55. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998 Nov; 16 (18): 1771-4
56. 56. Freund B, Gravenstein S, Elliot M, et al. Zanamivir: a review of clinical safety. Drug Saf 1999 Oct; 21 (4): 267-81
57. 57. Zanamivir: summary of product characteristics. 1999 Ware, UK: Glaxo Wellcome
58. 58. McBean AM, Babish JD, Warren JL. The impact and cost of influenza in the elderly. Arch Intern Med 1993; 153: 2105-11
59. 59. Cianci C, Krystal M. Development of untivirals against influenza. Expert Opin Invest Drug 1998 Feb; 7: 149-65
60. 60. Smith CB, Charette RP, Fox JP, et al. Lack of effect of oral ribavirin in naturally occurring influenza A virus (HINI) infection. J Infect Dis 1980; 141: 548-54
61. 61. Relenza studies in high-risk populations might show more efficacy - Cmte. FDC Pink Sheet 1999 Mar 1; 61: 3-5
62. 62. Aoki F, Fleming D, Lacey L, et al. Impact of treatment of influenza with zanamivir on patients' health status, sleep quality, productivity and Healthcare use [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1 : Toronto, 384
63. 63. Read RC. Treating influenza with zanamivir [letter]. Lancet 1998 Dec 12; 352: 1872-3
64. 64. Couch RB. A new antiviral agent for influenza - is there a clinical niche? N Engl J Med 1997 Sep 25; 337: 927-8
65. 65. Fleming DM. Treating influenza with zanamivir [letter]. Lancet 1999 Feb 20; 353: 668
66. 66. Silagy CA. Treating influenza with zanamivir [letter]. Lancet 1999 Feb 20; 353: 669
67. 67. Elliot AB, Noble S. Oseltamivir new drug profile. Drugs 1999 Nov; 58 (5). In press
68. 68. Fleming DM. Zanamivir. Drugs 1998 May; 55: 726